LARISSA II

We are a consortium of six partners with a single goal: the development and evaluation of a vaccine for the prevention of Rift Valley fever in humans. The project is named "LARISSA", acronym for Live Attenuated Rift Valley Fever Vaccine for Single Shot Application. Our hRVFV-4s candidate vaccine has been evaluated for safety and immunogenicity in a First in Human (FIH) Phase I study in Belgium in the LARISSA I project. The Phase II development is currently ongoing in our LARISSA II project, which is financed by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the EU Horizon Europe programme. CEPI aims to accelerate the development of vaccines against emerging infectious diseases and to enable equitable access to these vaccines in the face of outbreaks.